ArticleThe Journal of clinical endocrinology and metabolism2020
Unwitting Accomplices: Endocrine Disruptors Confounding Clinical Care.
Article in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Bisphenol A and cancer: a critical review of the epidemiologic literature with an emphasis on exposure assessment.Environmental health : a global access science source · 2026Review
- Plasticizing Diabetes Care: The Metabolic Threat of Plastic-Associated Endocrine Disruptors and Micro-/Nanoplastics in Clinical Medicine.Current diabetes reports · 2026Review
- Words Matter: Reflective Science Communication and Tradeoffs in Environmental Health Research.Environmental health perspectives · 2024Article
- Environmental Exposures and Pediatric Cardiology: A Scientific Statement From the American Heart Association.Circulation · 2024Review
- Empowering Student Pharmacists to Counsel Patients on Endocrine Disrupting Chemicals through Interactive Role-Play.Pharmacy (Basel, Switzerland) · 2024Article
- Effects of Behavioral, Clinical, and Policy Interventions in Reducing Human Exposure to Bisphenols and Phthalates: A Scoping Review.Environmental health perspectives · 2024Article
- Endocrine-disrupting chemicals: Mainstream recognition of health effects and implications for the practicing internist.Journal of internal medicine · 2024Article
- The regulation of endocrine-disrupting chemicals to minimize their impact on health.Nature reviews. Endocrinology · 2023Review
- The Pediatrician's Role in Protecting Children from Environmental Hazards.Pediatric clinics of North America · 2023Review
- The Minderoo-Monaco Commission on Plastics and Human Health.Annals of global health · 2023Review
- Stress and human health in diabetes: A report from the 19Journal of clinical and translational science · 2023Article
- Article
- Obesity II: Establishing causal links between chemical exposures and obesity.Biochemical pharmacology · 2022Review
- Inappropriately sweet: Environmental endocrine-disrupting chemicals and the diabetes pandemic.Advances in pharmacology (San Diego, Calif.) · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Burgeoning evidence over the last 25 years has identified myriad synthetic chemicals with the capacity to alter various aspects of hormone synthesis and action. These endocrine-disrupting chemicals (EDCs) have been linked to various diseases, including reproductive disorders, metabolic diseases, and developmental abnormalities, among others. Exposure to EDCs arises from industrial activity, use of personal and home care products, and consumption of contaminated food and water; however, the role of healthcare in exposing individuals to EDCs is grossly underappreciated. Indeed, through the use of medications as well as medical equipment and devices, healthcare providers are unknowing mediators of exposure to EDCs, chemicals that might not only promote disease but that may also antagonize the efficacy of treatments. The ethical implications of provider-dependent exposure are profound. A failure to disclose the endocrine-disrupting properties of medical interventions violates core principles of nonmaleficence, patient autonomy, and justice as well as the practice of informed consent. Furthermore, physicians' lack of knowledge regarding EDCs in medical practice artificially skews risk-benefit calculations that are fundamental to informed medical decision-making. To combat this underappreciated ethical challenge, urgent action is required. Healthcare providers must be educated about endocrine disruption. Known EDCs, defined by endocrinologists, should be clearly labeled on all medical products, and all medication components and devices should be screened for endocrine-disrupting properties. Finally, communication strategies must be devised to empower patients with knowledge about these risks. Providing ethically competent care requires an open acknowledgment of endocrine risks imposed by the medical community that have heretofore been ignored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.